Expanded Access to Drug and Device Products for Clinical Treatment

Tracy Ziolek (), Jessica L. Yoos (), Inna Strakovsky (), Praharsh Shah () and Emily Robison ()
Additional contact information
Tracy Ziolek: University of Pennsylvania
Jessica L. Yoos: University of Pennsylvania
Inna Strakovsky: University of Pennsylvania
Praharsh Shah: University of Pennsylvania
Emily Robison: Optum Labs

Chapter 124 in Principles and Practice of Clinical Trials, 2022, pp 2431-2451 from Springer

Abstract: Abstract Historically, patient access to investigational products (drugs or devices) has been limited to enrollment in clinical trials. However, enrollment of a patient into a clinical trial is not always possible for various reasons. Demand from patients and physicians for access to investigational products is due to the (sometimes remote) potential benefit to patients who have no other therapeutic alternatives. There are various options for the use of investigational drugs and devices in patient treatment through the Food and Drug Administration’s (FDA) expanded access program. These are outlined, along with criteria for use, submission requirements, approval processes, and associated practical guidance. There are four expanded access pathways for the use of investigational drugs: single-patient emergency use, single-patient treatment use, intermediate-size population treatment use, and treatment use. There are three expanded access pathways for the use of investigational devices: single-patient emergency use, single-patient or small group compassionate use, and treatment use. Additionally, treatment of a rare disease or condition with a Humanitarian Use Device (HUD) under a Humanitarian Device Exemption (HDE) is also possible.

Keywords: Expanded access; Emergency use; Compassionate use; Treatment use; Humanitarian use; Investigational drug; Investigational device; FDA; Life-threatening (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-319-52636-2_172

Ordering information: This item can be ordered from
http://www.springer.com/9783319526362

DOI: 10.1007/978-3-319-52636-2_172

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().